BIMI International Medical Inc. (BIMI) News
Filter BIMI News Items
BIMI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIMI News Highlights
- BIMI's 30 day story count now stands at 2.
- Over the past 21 days, the trend for BIMI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, NOV and PAY are the most mentioned tickers in articles about BIMI.
Latest BIMI News From Around the Web
Below are the latest news stories about BIMI INTERNATIONAL MEDICAL INC that investors may wish to consider to help them evaluate BIMI as an investment opportunity.
BIMI Stock Earnings: BIMI Intl Medical Reported Results for Q3 2023BIMI Intl Medical just reported results for the third quarter of 2023. |
BIMI International Medical Inc. Announces Third Quarter 2023 Financial ResultsNEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023. Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479, respectively. Revenues for the nine months ended September 30, 2023 and 2022 were $11,278,496 and $10,476,224, respectively. The revenues of the Zhongshan, Qiangsheng, Eura |
BIMI Announces Buyback of WarrantsNEW YORK, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, "BIMI"), a healthcare products and services provider, today announced its entry into material definitive agreements with certain of its warrant holders, pursuant to which BIMI agreed to buy back an aggregate of 7,066,913 warrants to purchase shares of common stock of the Company from these warrant holders. BIMI agreed to pay $0.30 for each share of common stock underlying the warrant, or an aggregate p |
BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”) today announced that on November 21, 2023, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Third Quarter Form 10-Q”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires lis |
BIMI International Medical Inc. Announces Second Quarter 2023 Financial ResultsNEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023. The Company reported a significant increase in gross margin underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the six months ended June 30, 2023 and 2022 were $8,755,303 and $5,543,745, respectively. Compared with the same period in 2022, |
BIMI Announces Subsidiary Phenix Bio Inc.’s New Product LaunchNEW YORK, NY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Phenix Bio Inc., a wholly owned subsidiary of BIMI International Medical Inc. (NASDAQ: BIMI), a leading global healthcare provider, announces the official launch of its "CUCA 3.0 Product Line through China Duty Free Group's (CDFG) online mini program sales platform. This significant milestone means China Duty Free’s 26 million members can now purchase Phenix’s products directly from CDFG, solidifying the previous purchase agreement between Phenix a |
BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of Hong Kong, Taiwan, and Macau Exclusive DistributorNEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”), as its exclusive distributor responsible for the distribution of Phenix’s 17 herbal supplements in Hong Kong, Taiwan and Macau. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases |
BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of Mainland China Non-Exclusive DistributorNEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”), as a distributor responsible for the distribution of Phenix’s 17 herbal supplements in Mainland China. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million i |
BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of ASEAN Exclusive DistributorNEW YORK, NY, Sept. 22, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, "BIMI"), a healthcare products and services provider today announced its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company, as its exclusive distributor responsible for the distribution of Phenix's 17 herbal supplements throughout the Association of Southeast Asian Nations (ASEAN) 10 member countries. Pursuant to the terms of a sales agreement entered on September 20, 2023, |
BIMI International Medical Inc. Announces Strategic Partnership by its Phenix Bio Inc. Subsidiary with China Duty Free GroupNEW YORK, NY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a leading global provider of healthcare services and innovative medical solutions, today announced the formation of a strategic partnership between its subsidiary, Phenix Bio Inc. (“Phenix”) and China Duty Free Group (“CDFG”), one of the largest and most influential state-owned duty-free retail enterprises in China. The Purchase Agreement between Phenix and CDFG, which became effective on Augu |